Safety Study to Explore Combination of Gefitinib (ZD1839, Iressa) and Radiotherapy in Non-Metastatic Prostate Cancer

Hypo-Combi Trial: Hypofractionated EBRT Plus HDR-BT Boost for Prostate Cancer

NCT05003752 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

Comparison of Two Radiation Therapy Regimens in Treating Patients With Stage II or Stage III Prostate Cancer

NCT00062309 ·Status: COMPLETED ·Phase: PHASE3

Randomized Trial of Suicide Gene Therapy and Prostate Cancer

NCT00583492 ·Status: COMPLETED ·Phase: PHASE2

Docetaxel + Prednisone With or Without Radiation for Castrate Resistant Prostate Cancer

NCT01087580 ·Status: WITHDRAWN ·Phase: PHASE2

Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer

NCT00116142 ·Status: COMPLETED ·Phase: PHASE3

Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer

NCT02023463 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Feasibility Study of a Dose Increase by a Boost of Curietherapy in Pulse Dose Rate (PDR) Associated With the Extern Radiotherapy in Prostate Cancer

NCT01039038 ·Status: TERMINATED ·Phase: PHASE2

Combination Casodex® and Iressa™ in Locally Advanced Prostate Cancer

NCT00319787 ·Status: COMPLETED ·Phase: PHASE2

Hypofractionated Radiation Therapy for Treating Prostate Cancer High-Risk Features Following Radical Prostatectomy

NCT03570827 ·Status: COMPLETED ·Phase: PHASE2

Study of Image-guided Dosimetry for Interstitial Prostate Brachytherapy

NCT00426959 ·Status: COMPLETED ·Phase: PHASE1

Response of Patients on Surveillance for Prostate Cancer to Dutasteride

NCT01525914 ·Status: COMPLETED

G-202 in the Neoadjuvant Setting Followed by Radical Prostatectomy in Patients With Prostate Cancer

NCT02381236 ·Status: COMPLETED ·Phase: PHASE2

Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer

NCT00541281 ·Status: COMPLETED ·Phase: PHASE2

Study of Docetaxel +153 Sm-EDTMP in Patients With Hormone-Refractory Prostate Cancer

NCT00559429 ·Status: COMPLETED ·Phase: PHASE1

Combination of Entinostat and Enzalutamide in Advanced Prostate Cancer

NCT03829930 ·Status: TERMINATED ·Phase: PHASE1

Lenalidomide and GM-CSF in Treating Patients With Prostate Cancer

NCT00939510 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Non-Interventional Study PREVENT

NCT02155998 ·Status: COMPLETED

Study to Evaluate the Safety, Pharmacokinetics, Tissue Distribution, Metabolism and Dosimetry of Two Prostate Cancer Imaging Agents

NCT00712829 ·Status: COMPLETED ·Phase: PHASE1

Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer

NCT00021450 ·Status: COMPLETED ·Phase: PHASE3

A Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine PDS01ADC in Localized High and Intermediate Risk Prostate Cancer Treated With Androgen Deprivation Therapy

NCT05361798 ·Status: RECRUITING ·Phase: PHASE2

Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer

NCT00226954 ·Status: TERMINATED ·Phase: PHASE2

An Efficacy and Safety Study of Intetumumab (CNTO 95) in Participants With Metastatic Hormone Refractory Prostate Cancer

NCT00537381 ·Status: COMPLETED ·Phase: PHASE2

Early Salvage Therapy for Patients With Advanced Features for Biochemical Relapse After Radical Prostatectomy for Localized Prostate Carcinoma In Correlation With Supposed Molecular-genetic Parameters of Higher Aggressiveness

NCT05232578 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3

Observation Study to Evaluate the Efficacy and Safety of Ifosfamide/Mesna in Patients With Metastatic Castration-resistant Prostate Cancer

NCT06236789 ·Status: RECRUITING

Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone Therapy

NCT00483561 ·Status: TERMINATED ·Phase: PHASE2